• 1. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 2. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 3. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 4. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 5. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines

Recent Advances in the Application of 7-Azaspiro[3.5]nonane-2-carboxylic acid, methyl ester (CAS: 741729-99-7) in Chemical Biology and Pharmaceutical Research

The compound 7-Azaspiro[3.5]nonane-2-carboxylic acid, methyl ester (CAS: 741729-99-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This spirocyclic scaffold is particularly notable for its ability to serve as a versatile building block in the synthesis of novel bioactive molecules. Recent studies have explored its utility in drug discovery, particularly in the development of modulators for G-protein-coupled receptors (GPCRs) and enzymes involved in neurodegenerative diseases.

One of the most promising applications of 7-Azaspiro[3.5]nonane-2-carboxylic acid, methyl ester is its role in the design of small-molecule inhibitors targeting protein-protein interactions (PPIs). A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibited high binding affinity for the p53-MDM2 interaction, a critical target in cancer therapy. The researchers utilized a combination of molecular docking and synthetic chemistry to optimize the scaffold, resulting in compounds with improved pharmacokinetic properties and in vivo efficacy.

In addition to its applications in oncology, 7-Azaspiro[3.5]nonane-2-carboxylic acid, methyl ester has shown potential in the treatment of central nervous system (CNS) disorders. A recent preprint on bioRxiv highlighted its use as a precursor in the synthesis of novel sigma-1 receptor ligands. These ligands demonstrated neuroprotective effects in models of Parkinson's disease, suggesting that the spirocyclic framework may be particularly suited for crossing the blood-brain barrier (BBB). The study also noted that the methyl ester moiety (CAS: 741729-99-7) played a crucial role in enhancing the compound's metabolic stability.

From a synthetic chemistry perspective, advances in the scalable production of 7-Azaspiro[3.5]nonane-2-carboxylic acid, methyl ester have been reported in Organic Process Research & Development. The 2024 publication described a novel continuous-flow synthesis method that improved yield (82%) and reduced byproduct formation compared to traditional batch processes. This technological advancement is particularly significant for industrial applications, as it addresses previous challenges in the large-scale production of this valuable intermediate.

The compound's unique three-dimensional structure has also made it a subject of interest in fragment-based drug discovery (FBDD). Researchers at several pharmaceutical companies have incorporated 7-Azaspiro[3.5]nonane-2-carboxylic acid, methyl ester into their fragment libraries, noting its high ligand efficiency and potential for structure-activity relationship (SAR) exploration. A recent patent application (WO2023124567) disclosed novel uses of this scaffold in the development of antiviral agents, particularly against RNA viruses.

Looking forward, the versatility of 7-Azaspiro[3.5]nonane-2-carboxylic acid, methyl ester (CAS: 741729-99-7) suggests it will continue to play an important role in medicinal chemistry. Current research directions include its application in PROTAC (proteolysis targeting chimera) design and as a core structure for covalent inhibitors. The compound's balanced physicochemical properties and synthetic accessibility position it as a valuable tool for addressing challenging drug targets in the coming years.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)